Abstract
Vardenafil orodispersible tablet (ODT) is a supralingual formulation of vardenafil that is available for the on-demand treatment of erectile dysfunction.
The pharmacokinetics of vardenafil ODT are not equivalent to those of the vardenafil film-coated tablet in that the ODT formulation provides consistently greater vardenafil systemic exposure. Therefore, the two formulations are not interchangeable.
The efficacy of on-demand vardenafil ODT 10 mg was established in the POTENT I and II studies, which were 6-week, randomized, double-blind, multinational trials in men with erectile dysfunction of at least 6 months duration. In both trials, vardenafil ODT improved erectile function significantly more than placebo, as indicated by International Index of Erectile Function-Erectile Function subscale scores at week 12 and overall erection success rates during treatment according to responses to questions 2 and 3 of the Sexual Encounter Profile (coprimary endpoints).
In a pooled analysis of both trials, vardenafil ODT improved erectile function regardless of age, severity of erectile dysfunction at baseline or the presence or absence of underlying medical conditions.
Vardenafil ODT was generally well tolerated in clinical trials, including in men aged ≥65 years, and adverse events were mostly mild or moderate in severity.
Similar content being viewed by others
References
Qaseem A, Snow V, Denberg DT, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Ann Int Med 2009 Nov 3; 151(9): 639–49
Rosen RC, Fisher WA, Eardley I, et al. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20(5): 607–17
Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Association of Urology. Eur Urol 2010 May; 57(5): 804–14
Keating GM, Scott LJ. Vardenafil: a review of its use in erectile dysfunction. Drugs 2003; 63(23): 2673–703
Giuliano F, Donatucci C, Montorsi F, et al. Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int Suppl 2005; 95(1): 110–6
Schneider T, Gleibner J, Merfort F, et al. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial. J Sex Med 2011 Oct; 8(10): 2904–11
Ishii N, Nagao K, Fujikawa K, et al. Vardenafil 20-mg demonstrated superior efficacy to 10 mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol 2006 Aug; 13(8): 1066–72
Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003 Mar; 26(3): 777–83
Shabsigh R, Duval S, Shah M, et al. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. Curr Med Res Opin 2007 Oct; 23(10): 2453–60
van Ahlen H, Wahle K, Kupper W, et al. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005 Nov; 2(6): 856–64
Miner M, Gilderman L, Bailen J, et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008 Jun; 5(6): 1455–67
Miner MM, Barnes A, Janning S. Efficacy of phosphodies-terase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study. J Sex Med 2010 May; 7(5): 1937–47
Giuliano F, Rubio-Aurioles E, Kennelly M, et al. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006 Jan 24; 66(2): 210–6
Giuliano F, Rubio-Aurioles E, Kennelly M, et al. Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury. Spine 2008 Apr 1; 33(7): 709–15
Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003 Oct; 170 (4 Pt 1): 1278–83
Nehra A, Grantmyre J, Nadel A, et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005 Jun; 173(6): 2067–71
Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008 Oct; 54(4): 924–31
Candy B, Jones L, Williams R, et al. Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review. BJU Int 2008 Aug; 102(4): 426–31
Zumbe J, Porst H, Sommer F, et al. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol 2008 Jul; 54(1): 204–10
Heinig R, Weimann B, Dietrich H, et al. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials. Clin Drug Invest 2011; 31(1): 27–41
European Medicines Agency. Levitra 10mg orodispersible tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000475/WC500039992.pdf [Accessed 2011 Sep6]
Bayer Healthcare Pharmaceuticals Inc. Staxyn (vardenafil hydrochloride) orally disintegrating tablets: prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf [Accessed 2011 Aug 18]
Kloner RA. Cardiovascular effects of the 3 phosphodies-terase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004 Nov 9; 110: 3149–55
Schwarz BG, Kloner RA. Drug interactions with phospho-diesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation 2010 Jul 6; 122: 88–95
Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002 Dec 4; 40(11): 2006–12
Fossa AA, Langdon G, Couderc J-P, et al. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil. Clin Pharmacol Ther 2011 Sep; 90(3): 449–54
Taner P, Basar MM, Unal B, et al. Effects of vardenafil on intraocular pressure and orbital hemodynamics. J Ocul Pharmacol Ther 2007 Jun; 23(3): 275–9
Jarvi K, Dula E, Drehobl M, et al. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels. J Urol 2008 Mar; 179(3): 1060–5
Ng CF, Wong A, Cheng CW, et al. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. J Urol 2008 Sep; 180(3): 1042–6
European Medicines Agency. Levitra 5 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu [Accessed 2011 Oct 17]
Sperling H, Debruyne F, Boermans A, et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010 Apr; 7 (4 Pt 1): 1497–507
Gittelman M, McMahon CG, Rodriguez-Rivera JA, et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010 Apr; 64(5): 594–603
Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 Jun; 49(6): 822–30
Sperling H, Gittelman M, Norenberg C, et al. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. J Sex Med 2011 Jan; 8(1): 261–71
Debruyne FMJ, Gittelman M, Sperling H, et al. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J Sex Med 2011 Oct; 8(10): 2912–23
Rosen RC, Cappelleri JC, Gendrano N III. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002 Aug; 14(4): 226–44
Hazell L, Cornelius V, Wilton L, et al. Mortality due to ischaemic heart disease in 15,659 patients prescribed vardenafil in general practice in England (2005): results from a prescription-event monitoring (PEM) study [abstract no. 387]. Pharmacoepidemiol Drug Saf 2009; 18 Suppl.: S168–9
Acknowledgements and Disclosures
The manuscript was reviewed by: R.K. Campbell, College of Pharmacy, Washington State University, Pullman (WA), USA; C. De Creé, Department of Medicine and Surgery, University of Rome, Rome, Italy; I.H. Derweesh, Division of Urology, Department of Surgery, University of California San Diego School of Medicine, La Jolla (CA), USA; S. Ferrero, Department of Obstetrics and Gynaecology, San Martino Hospital and University of Genoa, Genoa, Italy.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sanford, M. Vardenafil Orodispersible Tablet. Drugs 72, 87–98 (2012). https://doi.org/10.2165/11208270-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11208270-000000000-00000